MLL
RPRX icon

Moody Lynn & Lieberson’s Royalty Pharma RPRX Stock Holding History

Moody Lynn & Lieberson’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-68,165
Closed -$2.74M – 232
2022
Q3 		$2.74M Buy
68,165
+37,320
+121% +$1.59M 0.26% 68
2022
Q2 		$1.3M Buy
+30,845
New +$1.26M 0.12% 99

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moody Lynn & Lieberson's RPRX Position: Q4 2022 in Review

Moody Lynn & Lieberson sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 68,165 shares — an estimated $2.74M sold.

Moody Lynn & Lieberson first reported a position in RPRX in Q2 2022 and held it in 2 quarters. The position peaked at $2.74M in Q3 2022. 336 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

  • Moody Lynn & Lieberson reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 68,165 Royalty Pharma shares in Q4 2022, an estimated $2.74M.
  • Moody Lynn & Lieberson first reported a position in Royalty Pharma in Q2 2022 and held it in 2 quarters.
  • Moody Lynn & Lieberson's Royalty Pharma position peaked at $2.74M in Q3 2022.
  • 336 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Moody Lynn & Lieberson's 13F filing for Q4 2022, filed 1 Feb 2023.